Skip to main content Help with accessibility Skip to main navigation

Recommendations

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.

The list of resources will be updated as new material becomes available so please check back regularly for updates.

The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice. In the absence of any COVID-specific advice then the usual Pan Mersey guidance and RAG rating will still apply unless otherwise indicated.

This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.

Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.

Definitions and Criteria for Categorisation of Medicines

Documents

Date Added: 25 - Jan - 2017

The Pan Mersey Area Prescribing Committee does not recommend the prescribing of ASCORBIC ACID for any indication, other than scurvy.

Date Added: 24 - Feb - 2020

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of AVATROMBOPAG tablets (Doptelet®▼) for treating severe thrombocytopenia in adults with chronic liver disease having planned invasive procedures.

Date Added: 23 - May - 2017

The Pan Mersey Area Prescribing Committee does not recommend the prescribing of ELTROMBOPAG tablets (Revolade®) for Acquired Severe Aplastic Anaemia (SAA).

Date Added: 31 - Jan - 2019

The Pan Mersey Area Prescribing Committee recommends the prescribing of ELTROMBOPAG OLAMINE tablets (Revolade®) by Haematologists only, for chronic ITP in accordance with NICE TA293.

Date Added: 28 - Feb - 2018

The Pan Mersey Area Prescribing Committee recommends the prescribing of FERRIC MALTOL (Feraccru®) following specialist initiation for the treatment of iron deficiency anaemia in adult patients with inflammatory bowel disease.

Date Added: 21 - Jun - 2018

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of FERRIC MALTOL hard capsules (Feraccru®) for the treatment of iron deficiency in adults.

Date Added: 30 - Jan - 2020

The Pan Mersey Area Prescribing Committee recommends the prescribing of LUSUTROMBOPAG tablets (Mulpleo®▼), by specialists only, for treating severe thrombocytopenia in adults with chronic liver disease having planned invasive procedures in accordance with NICE TA617

Date Added: 30 - Mar - 2020

The Pan Mersey Area Prescribing Committee recommends the prescribing of PATIROMER powder for oral suspension (Veltassa®▼) for emergency treatment of life-threatening hyperkalaemia in adults in accordance with NICE TA623.

Date Added: 30 - Mar - 2020

The Pan Mersey Area Prescribing Committee recommends the prescribing of PATIROMER powder for oral suspension (Veltassa®▼) for persistent hyperkalaemia in adults following initiation by a specialist in accordance with NICE TA623.

Date Added: 26 - Jun - 2019

RITUXIMAB (Truxima®▼, Rixathon®▼)The Pan Mersey Area Prescribing Committee recommends the prescribing of rituximab by specialists only, for immune (idiopathic) thrombocytopenic purpura before romiplostin and eltrombopag.

Date Added: 31 - Jan - 2019

The Pan Mersey Area Prescribing Committee recommends the prescribing of ROMIPLOSTIM SC injection (Nplate®), by Haematologists only, for chronic immune (idiopathic) thrombocytopenic purpura (ITP) in accordance with NICE TA221.

Date Added: 25 - Sep - 2019

The Pan Mersey Area Prescribing Committee recommends the prescribing of SODIUM ZIRCONIUM CYCLOSILICATE powder for oral suspension (Lokelma®▼) for the treatment of hyperkalaemia, within secondary care only, in line with NICE TA599.